

CARLO ROSA:

Thank you, PG. And so, before we move to the Q&A session, let me just wrap up what has been discussed in the last hour or so, and what are the key takeaway messages. I believe we are in much better shape now than before the Luminex acquisition for all the reasons that I think have been highlighted. We are stronger from a technological point of view; we are stronger when it comes to our geographical position, and we are able to capture the growth opportunities.

The Luminex integration in the last 2 years has been completed, so now the Luminex becomes an engine for growth and new products development. We're going to be launching 3 new platforms in the next 3 years and 10 new products. 3 legs, better than one. So the business is resilient, better growth opportunities, and the up and down of business and geographies, which can always happen, clearly has been de-risked, because we are present in 3 different business areas.

Focus on innovation. The plan requires Diasorin to invest over \$200 million in the next years or so to continue to fuel innovation. So you have seen what's in the pipeline, but we will continue to develop new pipeline in the next years to come.

Clearly, we have a strategic imperative. We need to increase the critical mass in the US. Today, it is already 50% of our revenues, and we need to become bigger in the US because it's the market that's base for innovation, base for talent and we believe that we have talent and innovation to continue to develop that market.

Last but not least, you have seen that, as far as, the capital allocation is concerned, we are deleveraging very fast company, and so as Mr. Denegri said at the beginning, I think that as a shareholder and as management, we are able to continue to look outside and see if there are opportunities for Diasorin to grow the business in a non-organic way.

At this point, I'm going to leave the podium to the audience for the Q&A session. Thank you.